Company Overview

Pluri Inc. is a biotechnology company focused on the development and commercialization of cell-based therapeutic and manufacturing platforms, primarily leveraging placenta-derived cell technologies. The company operates within the biotechnology and life sciences industries, with applications spanning regenerative medicine, immunotherapy, and large-scale cell production. Pluri’s core value proposition centers on its ability to expand and differentiate cells at industrial scale while maintaining biological consistency, addressing key bottlenecks in cell therapy manufacturing.

The company’s primary business lines include the development of proprietary cell expansion and differentiation technologies and therapeutic candidates targeting inflammatory, hematologic, and immune-related conditions. Pluri traces its origins to Israel, where it was founded to commercialize placental cell science developed through academic and clinical research. Over time, it evolved from a research-focused entity into a publicly traded biotechnology company with both therapeutic development and contract manufacturing ambitions.

Business Operations

Pluri conducts operations through integrated platforms that support cell therapy development, cell-based contract development and manufacturing, and internally developed therapeutic programs. Revenue generation has historically been driven by research collaborations, manufacturing services, and government or institutional grants, while therapeutic programs remain largely in clinical or preclinical stages. The company’s core technological asset is its proprietary 3D bioreactor-based cell expansion system, designed to enable scalable and cost-efficient production of adherent cells.

Operations span domestic activities in Israel and international engagements, particularly in the United States capital markets following its public listing. Pluri controls proprietary know-how, patents, and manufacturing processes related to placental cell expansion. The company operates through wholly owned subsidiaries, including Pluri-CDMO Ltd., which focuses on contract manufacturing services for third-party cell therapy developers. No material joint ventures have been conclusively verified in public disclosures.

Strategic Position & Investments

Pluri’s strategic direction emphasizes positioning itself as both a cell therapy innovator and a cell manufacturing enabler. Growth initiatives include advancing its therapeutic pipeline toward clinical milestones while expanding contract development and manufacturing (CDMO) services to external biotechnology partners. The company has publicly stated its intent to capitalize on increasing global demand for scalable cell production infrastructure.

The company has pursued selective acquisitions and internal investments to strengthen its manufacturing capabilities and intellectual property base. Notable subsidiaries include Pluri-CDMO Ltd., which represents a strategic effort to diversify revenue beyond proprietary therapeutics. Pluri is also involved in emerging areas such as cell-based solutions for inflammation, immune modulation, and potential medical countermeasures, though the commercial timelines for these initiatives remain uncertain based on available public sources.

Geographic Footprint

Pluri is headquartered in Israel, which serves as the center for its research, development, and manufacturing operations. The company maintains a market presence in North America, primarily through investor engagement and strategic collaborations linked to its public listing and biotechnology partnerships.

While Pluri does not currently report large-scale commercial operations across multiple continents, it positions itself as a globally oriented biotechnology company with the capacity to serve international partners through its cell manufacturing platform. Its strategic focus remains on expanding influence in Israel and the United States, with potential future expansion into additional regions dependent on clinical progress and commercial demand.

Leadership & Governance

Pluri was founded by scientists and entrepreneurs with backgrounds in cell biology and biotechnology commercialization. The leadership team emphasizes a strategy centered on scientific rigor, scalable manufacturing, and long-term value creation through platform-based biotechnology development. Corporate governance aligns with public company requirements following its listing on U.S. markets.

Key executives include:

• Yaky Yanay – President and Chief Executive Officer
• Ran Dror – Chief Financial Officer
• Dr. Amir Pelled – Founder and Chief Scientific Officer
• Nadav Friedmann – Vice President, Research and Development

Leadership philosophy, as reflected in public statements and filings, focuses on translating placental cell science into commercially viable therapies and manufacturing solutions while maintaining disciplined capital allocation.